Avid Bioservices Inc is a company that values innovation, integrity, and reliability. With a corporate philosophy focused on delivering high-quality biologics manufacturing, Avid Bioservices Inc aims to provide efficient and dependable solutions to the biotechnology and pharmaceutical industries. The company prides itself on its commitment to meeting client needs, exceeding expectations, and maintaining strong relationships with its partners. Avid Bioservices Inc's dedication to cutting-edge technologies and compliance with regulatory standards enables them to consistently deliver exceptional, cost-effective services. By upholding these values and corporate philosophy, Avid Bioservices Inc has established itself as a trusted and leading provider in the biopharmaceutical contract development and manufacturing industry.

Avid Bioservices Inc is primarily present in the United States.

Avid Bioservices Inc has achieved several significant milestones. The company successfully completed the expansion of its Myford manufacturing facility, which increased its production capacity to meet growing demand. Additionally, Avid Bioservices achieved key regulatory milestones by obtaining FDA approval for multiple biologics produced at its facilities. The company also secured several strategic partnerships and collaborations with renowned pharmaceutical companies, further establishing its position in the market. Furthermore, Avid Bioservices successfully delivered consistent and high-quality manufacturing services, leading to increased customer satisfaction and repeat business. These achievements reflect the company's dedication to innovation, quality, and providing exceptional biomanufacturing solutions.

Avid Bioservices Inc is a reputable biotechnology company with a rich history and background. Established in 1981, the company has become a leading provider of biomanufacturing services, specializing in the development and production of monoclonal antibodies and recombinant proteins. Avid Bioservices Inc is committed to delivering high-quality, innovative solutions to the biotech industry, serving both large pharmaceutical companies and small biotech firms. With state-of-the-art facilities and a team of experienced scientists, the company has earned a commendable reputation for its expertise in cell culture, process development, and manufacturing. Avid Bioservices Inc consistently strives towards advancing healthcare through its cutting-edge biomanufacturing capabilities.

The main competitors of Avid Bioservices Inc in the market are Cytovance Biologics, Inc., Lonza Group Ltd., AbbVie Inc., and Catalent, Inc.

Avid Bioservices Inc is primarily active in the biotechnology and pharmaceutical industries.

Avid Bioservices Inc is a leading contract development and manufacturing organization (CDMO) that provides comprehensive services for the biotechnology and pharmaceutical industries. The company's business model revolves around offering a wide range of solutions for the development, manufacturing, and commercialization of biologic products. Avid Bioservices specializes in the production of monoclonal antibodies, recombinant proteins, and other biologics. Their state-of-the-art facilities, experienced team, and quality-driven approach enable them to deliver efficient and cost-effective solutions to their clients. With a focus on meeting regulatory requirements and maintaining high standards, Avid Bioservices Inc continues to play a crucial role in supporting biopharmaceutical companies in advancing their therapeutic innovations.

Avid Bioservices KGV ir -3,74.

Avid Bioservices KUV ir 3,76.

AlleAktien kvalitātes vērtējums Avid Bioservices ir 4/10.

Avid Bioservices apgrozījums ir 139,91 milj. USD.

Avid Bioservices peļņa ir -140,75 milj. USD.

Avid Bioservices Inc is a biopharmaceutical company specializing in the development and manufacturing of biopharmaceuticals. The company offers integrated development services and manufacturing services to various customers, including pharmaceutical and biotech companies. The company provides a wide range of services, including manufacturing of clinical batches, scale-up processes, and process optimization. They have a fully integrated GMP production facility in California, USA, and produce both recombinant proteins and monoclonal antibodies. One of the main divisions of Avid Bioservices is the development of cell lines for biopharmaceutical production. They use their expertise in molecular biology to select and develop recombinant cell lines suitable for biopharmaceutical production. They work closely with customers to develop customized cell lines tailored to the requirements of biopharmaceuticals. Another division of Avid Bioservices is the manufacturing of clinical batches of biopharmaceuticals. They have the expertise and capacity to scale production processes and conduct commercial production of biopharmaceuticals. They are capable of producing batches in various sizes, including batches for Phase I, Phase II, and Phase III clinical studies. The company also offers process optimization services to improve the production of biopharmaceuticals. They have extensive experience in transferring production processes from the laboratory to the production scale. They utilize their expertise in process optimization to improve production efficiency and quality, and reduce production costs. The products of Avid Bioservices include a wide range of recombinant proteins and monoclonal antibodies, such as enzymes, hormones, growth factors, antibodies, and other biopharmaceuticals. They work closely with customers to develop customized biopharmaceuticals that meet the specific requirements of diseases. In collaboration with its customers, Avid Bioservices aims to accelerate the clinical development of biopharmaceuticals and expand the available selection of biopharmaceuticals. The company strives to make the production of biopharmaceuticals more efficient, high-quality, and cost-effective. In summary, Avid Bioservices is a biopharmaceutical company specializing in integrated development services and manufacturing services. They offer a wide range of products and services, including the development of cell lines, manufacturing of clinical batches, process optimization, and production of recombinant proteins and monoclonal antibodies. Avid Bioservices aims to accelerate the development of biopharmaceuticals and improve the production of biopharmaceuticals in terms of efficiency, quality, and cost-effectiveness.

Avid Bioservices izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Avid Bioservices vai uzņēmums nedod dividendes.

Avid Bioservices ISIN ir US05368M1062.

Avid Bioservices WKN ir A2JBKV.

Avid Bioservices simbols ir CDMO.

Pēdējo 12 mēnešu laikā Avid Bioservices maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Avid Bioservices plāno maksāt dividendes 0 USD apmērā.

Avid Bioservices pašreizējā dividendu rentabilitāte ir .

Avid Bioservices maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Avid Bioservices pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Avid Bioservices tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Avid Bioservices apmērā 0 USD, kas tika izmaksāta 16.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.07.2024..

Pēdējās dividendes izmaksa notika 16.07.2024..

Gadā 2023, Avid Bioservices izmaksāja 0 USD dividendes.

Avid Bioservices dividendes tiek izmaksātas USD.